ATN cerebrospinal fluid biomarkers in dementia with Lewy bodies: Initial results from the United States Dementia with Lewy Bodies Consortium.
- Resource Type
- Academic Journal
- Authors
- Jain L; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Khrestian M; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Formica S; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Tuason ED; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.; Pillai JA; Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.; Rao S; Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.; Oguh O; Cleveland Clinic Lou Ruvo Center for Brain Health-Las Vegas, Cleveland Clinic, Las Vegas, Nevada, USA.; Lippa CF; Cleveland Clinic Lou Ruvo Center for Brain Health-Las Vegas, Cleveland Clinic, Las Vegas, Nevada, USA.; Lopez OL; Cognitive Disorders & Comprehensive Alzheimer's Disease Center, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.; Berman SB; Department of Neurology, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.; Tsuang DW; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, Washington, USA.; Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA.; Zabetian CP; Geriatric Research, Education, and Clinical Center, VA Puget Sound Health Care System, Seattle, Washington, USA.; Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA.; Irwin DJ; Department of Neurology, University of Pennsylvania Health System, Philadelphia, Pennsylvania, USA.; Digital Neuropathology Laboratory, Philadelphia, Pennsylvania, USA.; Lewy Body Disease Research Center of Excellence, Philadelphia, Pennsylvania, USA.; Frontotemporal Degeneration Center, Philadelphia, Pennsylvania, USA.; Galasko DR; Department of Neurosciences, University of California, San Diego, California, USA.; Litvan I; Department of Neurosciences, University of California, San Diego, California, USA.; Marder KS; Columbia University Irving Medical Center, New York, New York, USA.; Honig LS; Department of Neurosciences, University of California, San Diego, California, USA.; Fleisher JE; Department of Neurological Sciences, Rush Medical College, Chicago, Illinois, USA.; Galvin JE; Department of Neurology, Comprehensive Center for Brain Health, University of Miami Miller School of Medicine, Miami, Florida, USA.; Bozoki AC; Department of Neurology, University of North Carolina, Chapel Hill, North Carolina, USA.; Taylor AS; Lewy Body Dementia Association, Lilburn, Georgia, USA.; Sabbagh MN; Department of Neurology, Barrow Neurological Institute, Phoenix, Arizona, USA.; Leverenz JB; Cleveland Clinic Lou Ruvo Center for Brain Health, Cleveland Clinic, Cleveland, Ohio, USA.; Bekris LM; Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio, USA.
- Source
- Publisher: John Wiley & Sons, Ltd Country of Publication: United States NLM ID: 101231978 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1552-5279 (Electronic) Linking ISSN: 15525260 NLM ISO Abbreviation: Alzheimers Dement Subsets: MEDLINE
- Subject
- Language
- English
Introduction: The National Institute on Aging - Alzheimer's Association (NIA-AA) ATN research framework proposes to use biomarkers for amyloid (A), tau (T), and neurodegeneration (N) to stage individuals with AD pathological features and track changes longitudinally. The overall aim was to utilize this framework to characterize pre-mortem ATN status longitudinally in a clinically diagnosed cohort of dementia with Lewy bodies (DLB) and to correlate it with the post mortem diagnosis.
Methods: The cohort was subtyped by cerebrospinal fluid (CSF) ATN category. A subcohort had longitudinal data, and a subgroup was neuropathologically evaluated.
Results: We observed a significant difference in Aβ 42/40 after 12 months in the A+T- group. Post mortem neuropathologic analyses indicated that most of the p-Tau 181 positive (T+) cases also had a high Braak stage.
Discussion: This suggests that DLB patients who are A+ but T- may need to be monitored to determine whether they remain A+ or ever progress to T positivity.
Highlights: Some A+T- DLB subjects transition from A+ to negative after 12-months. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Clinically diagnosed DLB with LBP-AD (A+T+) maintain their positivity. Monitoring of the A+T- sub-type of DLB may be necessary.
(© 2023 The Authors. Alzheimer's & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer's Association.)